NYSE:CBT - Cabot Stock Price, News & Analysis

Cabot trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBT."

Cabot declared a quarterly dividend on Friday, July 12th. Stockholders of record on Friday, August 30th will be paid a dividend of $0.35 per share on Friday, September 13th. This represents a $1.40 annualized dividend and a dividend yield of 3.69%. The ex-dividend date is Thursday, August 29th. View Cabot's Dividend History.

Cabot declared that its Board of Directors has authorized a share buyback program on Monday, July 16th 2018, which authorizes the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 10.3% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board believes its stock is undervalued.

Cabot Corp (NYSE:CBT) released its quarterly earnings data on Monday, August, 5th. The specialty chemicals company reported $1.00 earnings per share for the quarter, meeting the Zacks' consensus estimate of $1.00. The specialty chemicals company earned $845 million during the quarter, compared to analyst estimates of $858.86 million. Cabot had a net margin of 6.49% and a return on equity of 18.60%. The company's revenue for the quarter was down 1.1% on a year-over-year basis. During the same period in the previous year, the company posted $1.06 EPS. View Cabot's Earnings History.

Cabot is scheduled to release their next quarterly earnings announcement on Monday, November 4th 2019. View Earnings Estimates for Cabot.

4 equities research analysts have issued 1-year target prices for Cabot's shares. Their forecasts range from $40.00 to $76.00. On average, they expect Cabot's share price to reach $50.50 in the next year. This suggests a possible upside of 33.2% from the stock's current price. View Analyst Price Targets for Cabot.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cabot in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cabot.

News stories about CBT stock have trended positive this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cabot earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news coverage about the specialty chemicals company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term. View News Stories for Cabot.

Cabot saw a decrease in short interest during the month of July. As of July 31st, there was short interest totalling 788,300 shares, a decrease of 7.6% from the June 30th total of 853,500 shares. Based on an average trading volume of 365,400 shares, the days-to-cover ratio is presently 2.2 days. Currently, 1.4% of the company's shares are short sold. View Cabot's Current Options Chain.

Some companies that are related to Cabot include Versum Materials (VSM), Platform Specialty Products (PAH), WD-40 (WDFC), Element Solutions (ESI), Orion Engineered Carbons (OEC), Advanced Emissions Solutions (ADES), Flotek Industries (FTK), Pure Bioscience (PURE), HighCom Global Security (HCGS), GlyEco (GLYE), Artemis Therapeutics (ATMS) and Ener-Core (ENCR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cabot investors own include Broadcom (AVGO), Energy Transfer LP Unit (ET), JPMorgan Chase & Co. (JPM), Oracle (ORCL), Adobe (ADBE), Gilead Sciences (GILD), AT&T (T), Wells Fargo & Co (WFC), Cisco Systems (CSCO) and Micron Technology (MU).

Cabot's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.20%), BlackRock Inc. (9.31%), Vanguard Group Inc. (8.93%), LSV Asset Management (4.78%), Bank of New York Mellon Corp (4.63%) and Earnest Partners LLC (4.07%). Company insiders that own Cabot stock include Brian A Berube, Gottberg Friedrich Von, Hobart Kalkstein, James Patrick Kelly, Michael M Morrow, Nicholas S Cross, Patrick M Prevost and Sean D Keohane. View Institutional Ownership Trends for Cabot.

CBT stock was sold by a variety of institutional investors in the last quarter, including Quest Capital Management Inc. ADV, BlackRock Inc., BlackRock Inc., Russell Investments Group Ltd., Grantham Mayo Van Otterloo & Co. LLC, Vanguard Group Inc., AQR Capital Management LLC and Los Angeles Capital Management & Equity Research Inc.. View Insider Buying and Selling for Cabot.

CBT stock was acquired by a variety of institutional investors in the last quarter, including Earnest Partners LLC, Nuveen Asset Management LLC, Bank of America Corp DE, Royal Bank of Canada, Deprince Race & Zollo Inc., Wells Fargo & Company MN, WBI Investments Inc. and Icon Advisers Inc. Co.. View Insider Buying and Selling for Cabot.

Shares of CBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBT stock can currently be purchased for approximately $37.90.

Cabot has a market capitalization of $2.19 billion and generates $3.24 billion in revenue each year. The specialty chemicals company earns $-113,000,000.00 in net income (profit) each year or $4.03 on an earnings per share basis. Cabot employs 4,600 workers across the globe.View Additional Information About Cabot.

The official website for Cabot is http://www.cabot-corp.com/.

Cabot's mailing address is TWO SEAPORT LANE SUITE 1300, BOSTON MA, 02210. The specialty chemicals company can be reached via phone at 617-345-0100 or via email at [email protected]